Entheon Biomedical Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENBI.CN research report →
Companywww.entheonbiomedical.com
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders.
- CEO
- Timothy Ko
- IPO
- 2018
- Employees
- 1
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $1.39M
- P/E
- -4.27
- P/S
- 0.00
- P/B
- 4.28
- EV/EBITDA
- -3.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.74%
- ROIC
- -103.21%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-324,012 · -1.89%
- EPS
- $-0.02 · 41.12%
- Op Income
- $-334,223
- FCF YoY
- 11.52%
Performance & Tape
- 52W High
- $0.45
- 52W Low
- $0.07
- 50D MA
- $0.09
- 200D MA
- $0.10
- Beta
- 1.59
- Avg Volume
- 8.90K
Get TickerSpark's AI analysis on ENBI.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ENBI.CN Coverage
We haven't published any research on ENBI.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENBI.CN Report →